Literature DB >> 27365092

Study of warfarin utilization in hospitalized patients: analysis of possible drug interactions.

Camilo Molino Guidoni1, Helen Palmira Miranda Camargo2, Paulo Roque Obreli-Neto3, Edmarlon Girotto1, Leonardo Regis Leira Pereira3.   

Abstract

Background Drug-drug interactions in patients taking warfarin may contribute to a higher risk of adverse events. Objective To identify and evaluate the prevalence and characteristics of potential DDIs with warfarin. Methods A cross-sectional study was performed in a Brazilian tertiary hospital. The electronic prescriptions of the patients receiving warfarin between January 2004 and December 2010 were analyzed. Socio-demographic, clinical, and therapeutic variables were collected. Warfarin drug-drug interactions were classified as either risk A, B, C, D, or X according to the Lexi-Interact™ Online database. Results A total of 3048 patients were identified who were prescribed warfarin. Of the 154,161 total drug prescriptions issued, 42,120 (27.3 %) were for warfarin. Evaluation of the prescriptions showed that 63.1 and 0.1 % of patients received concomitant drugs classified as having class D or X risk. It was found that 20,539 (48.7 %) prescriptions had at least one drug with a D or X risk. Patients were prescribed an average of 1.4 (±0.4) concomitant medications with a class D or X warfarin-DDI risk, the most frequent being acetylsalicylic acid and amiodarone. Conclusion The results demonstrate a high prevalence of concomitant drug prescriptions with the potential for clinically relevant DDIs with warfarin, the most frequent being acetylsalicylic acid and amiodarone.

Entities:  

Keywords:  Brazil; Drug-drug interaction; Pharmacoepidemiology; Unified Health System; Warfarin

Mesh:

Substances:

Year:  2016        PMID: 27365092     DOI: 10.1007/s11096-016-0336-z

Source DB:  PubMed          Journal:  Int J Clin Pharm


  8 in total

1.  Reliability and validity of 5 databases for the identification of warfarin-medication interactions.

Authors:  Aaron Kornblith; Kennon Heard
Journal:  Clin Appl Thromb Hemost       Date:  2010-11-15       Impact factor: 2.389

2.  Understanding adverse drug reactions in older adults through drug-drug interactions.

Authors:  A Marengoni; L Pasina; C Concoreggi; G Martini; F Brognoli; A Nobili; G Onder; D Bettoni
Journal:  Eur J Intern Med       Date:  2014-10-11       Impact factor: 4.487

3.  Utilization review of concomitant use of potentially interacting drugs in Thai patients using warfarin therapy.

Authors:  Surachai Kotirum; Nathorn Chaiyakunapruk; Katechan Jampachaisri; Supharat Wattanasombat; Ponlapat Rojnuckarin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-02       Impact factor: 2.890

Review 4.  Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis.

Authors:  Supinya Dechanont; Sirada Maphanta; Bodin Butthum; Chuenjid Kongkaew
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-03-10       Impact factor: 2.890

5.  Co-Prescribing of Potentially Interacting Drugs during Warfarin Therapy - A Population-Based Register Study.

Authors:  Maria Rikala; Milka Hauta-Aho; Arja Helin-Salmivaara; Riitta Lassila; Maarit Jaana Korhonen; Risto Huupponen
Journal:  Basic Clin Pharmacol Toxicol       Date:  2015-01-19       Impact factor: 4.080

Review 6.  Systematic overview of warfarin and its drug and food interactions.

Authors:  Anne M Holbrook; Jennifer A Pereira; Renee Labiris; Heather McDonald; James D Douketis; Mark Crowther; Philip S Wells
Journal:  Arch Intern Med       Date:  2005-05-23

7.  Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands.

Authors:  Fernie J A Penning-van Beest; Jeroen Koerselman; Ron M C Herings
Journal:  Pharm World Sci       Date:  2007-04-24

8.  Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study.

Authors:  Gebrehiwot Teklay; Nuredin Shiferaw; Befikadu Legesse; Mebratu Legesse Bekele
Journal:  Thromb J       Date:  2014-09-17
  8 in total
  2 in total

1.  Effective INR Level May Be Delayed in Secondary Prevention of Stroke Due to Atrial Fibrillation with Warfarin in the Patients with Diabetes Mellitus.

Authors:  Türkan Acar; Yeşim Güzey Aras; Sıdıka Sinem Gül; Bilgehan Atilgan Acar
Journal:  Noro Psikiyatr Ars       Date:  2018-10-24       Impact factor: 1.339

2.  Long-Term Statin Administration Does Not Affect Warfarin Time in Therapeutic Range in Australia or Singapore.

Authors:  Nijole Bernaitis; Chi Keong Ching; Siew Chong Teo; Tony Badrick; Andrew K Davey; Julia Crilly; Shailendra Anoopkumar-Dukie
Journal:  J Clin Med       Date:  2018-05-01       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.